Alseres Pharmaceuticals Inc.

Dr. Mark R. Hurtt was named Boston Life Sciences' Chief Medical Officer in October 2005. Most recently, Dr. Hurtt was Senior Director of Clinical Research at Neurogen Corporation in Branford, CT.. Prior to Neurogen, Dr. Hurtt was Director of Drug Development and Director of Clinical Research at Pfizer Global Research and Development in Ann Arbor, MI. During his career, Dr. Hurtt has overseen CNS development programs in Parkinson's Disease, Alzheimer's disease, schizophrenia, pain, anxiety, and depression. Dr. Hurtt is Board certified in Neurology and Neuropathology. He received his medical degree from Jefferson Medical College and served as a Medical Officer in the United States Navy. He trained in neurology and neuropathology and was an assistant professor in the Departments of Neurology and Pathology at the University of Pittsburgh.

A co-founder, Dr. Cusack has overall responsibility for managing the non-clinical development and drug discovery programs at Aderis Pharmaceuticals. He brings over 30 years of chemistry and pharmacology management experience with expertise in the therapeutic application of adenosine and adenine nucleotide derivatives. He teaches the FDA and ICH non-clinical requirements for international drug development and directs the pharmacology training courses for the Pharmaceutical Education and Research Institute. Dr. Cusack maintains a faculty position as adjunct professor at the University of California, Irvine. Previously he held academic appointments at the University of Cambridge and King's College, London. Dr. Cusack received his Ph. D. in Organic Chemistry from the University of Bradford, U.K.

Dr. Thorn was named Senior Vice President of Program Operations in December 2001, after serving as Director of Product Development since 1997. Prior to joining BLSI, Dr. Thorn was Director of Technology Transfer at Boston Biomedica, Inc. from 1995 to 1997, Director of Research and Development at Verigen, Inc. from 1992 to 1995, Director of the Immunology and Antibody Services groups at Baxter Diagnostics, Inc. from 1989 to 1992, and was a Research and Development Scientist at Cambridge BioTech Corporation from 1983 to 1989. From 1979 to 1983, Dr. Thorn was an Assistant Professor at the University of Pennsylvania where he did research on the immune response to Bovine Leukemia Virus. From 1976 to 1979, he did research on the immune response to ultraviolet light-induced tumors in mice. Dr. Thorn did post-doctoral work on T-cell mediated cytolysis at Johns Hopkins University. His Ph.D. was earned at the University of Pennsylvania and his B.A. from the University of California at San Diego. Dr. Thorn has published more than 20 scientific articles in peer-reviewed journals, and holds two patents.

William Guinness joined the Board of Directors in July 2006. Mr. Guinness has been Chairman of Sibir Energy plc since 1999 and had additional roles with Pentex Energy plc and Pentex Oil plc. Mr. Guinness has been involved with various private venture capital operations, which cover areas as diverse as metal manufacturing, general aviation, and fine art consultancy. Mr. Guinness is also a director of a number of private companies involved in a wide range of commercial activities. Mr. Guinness previously served on the Company's Board of Directors from June 30, 2003 to September 20, 2003.

Dr. Langer has served as a scientific consultant and director since June 2002. Dr. Langer is currently the Chairman of the Company s Scientific Advisory Board. Dr. Langer is a co-founder of Sontra Medical, Inc. Since 1979, Dr. Langer has been Germeshausen Professor of Chemical and Biomedical Engineering at the Massachusetts Institute of Technology. Dr. Langer is also currently a director of Momenta Pharmaceuticals, Inc., a biotechnology company developing drugs based on sugar sequencing technology, Boston Life Sciences, Inc., a company focused on research and development of therapeutic and diagnostic products, and Wyeth, a pharmaceutical and consumer healthcare products company. Dr. Langer received his B.S. from Cornell University in 1970 and his Ph.D. from MIT in 1974, both in chemical engineering.

James Fawcett is chairman of the Cambridge University Centre for Brain Repair, and director of medical studies at King's College. He qualified as a physician at St Thomas' Hospital, and became a full time researcher after 4 years of clinical practice. His main research interest is in nerve fibre regeneration, and particularly the way in which inhibitory molecules in scar tissue block regeneration after spinal cord injury. He has been responsible for experiments showing that the enzyme chondroitinase can break down inhibitory molecules in scar tissue, and allow nerve fibre regeneration and functional recovery after spinal cord injury.

Professor of Neurosurgery and McLaughlin Scholar in Molecular Medicine, University of Toronto; Chairman of the Spinal Program, Toronto Western Hospital; Medical Director of the Krembil Neuroscience Center, University Health Network and Krembil Chair in Neural Repair and Regeneration. Michael G. Fehlings M.D. Ph.D. FRCSC FACS is a Professor of Neurosurgery and McLaughlin Scholar in Molecular Medicine at the University of Toronto, Chairman of the Spinal Program at the Toronto Western Hospital, Medical Director of the Krembil Neuroscience Center at the University Health Network and Krembil Chair in Neural Repair and Regeneration. His main clinical interests are in complex spinal neurosurgery, and his research focus is in molecular mechanisms underlying spinal cord injury and translational research related to spine and spinal cord conditions. In this regard, Dr. Fehlings directs a New Emerging Team in Spinal Cord Injury Regenerative Medicine and Nanotechnology which is funded by the Canadian Institutes of Health Research. Dr. Fehlings is a co-principal investigator in the Christopher and Dana Reeve Foundation funded North American Clinical Trials Network, co-director of the Canadian Spinal Cord Injury Translational Research Network and co-chair of the renowned Spine Trauma Study Group. He is the principal investigator in the Cethrin PhaseI/IIa clinical trial.